Skip to main content

Advertisement

Table 7 Meta-analysis of association between HER family members, pathway-related proteins expression and OS

From: Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients

Proteins Tumor location OS Number of studies Number of patients Heterogeneity Model RR(95%CI) P value
I 2 (%) P value
HER2-HER3 Digestive tract 1-year OS 5 969 48 0.11 FE 0.71(0.36,1.40) 0.32
3-year OS 5 969 0 0.48 RE 1.27(0.98,1.64) 0.07
5-year OS 4 847 66 0.03 RE 1.31(1.00,1.72) 0.049
HER3 Stomach 1-year OS 6 888 14 0.33 FE 1.85(1.32,2.58) <0.001
3-year OS 5 813 46 0.12 FE 1.53(1.27,1.85) <0.001
5-year OS 3 503 85 0.001 RE 2.18(1.15,4.14) 0.02
Akt Stomach 1-year OS 1 98 2.09(0.50,8.83) 0.32
3-year OS 1 98 1.59(0.73,3.43) 0.24
5-year OS 1 98 1.43(1.06,1.03) 0.02
p-Akt Stomach 1-year OS 8 1558 66 0.004 RE 0.96(0.56,1.65) 0.89
3-year OS 8 1558 75 0 RE 1.19(0.84,1.69) 0.32
5-year OS 7 1513 79 0 RE 1.15(0.84,1.58) 0.37
mTOR Stomach 1-year OS 3 1179 90 0 RE 1.02(0.38,1.2.73) 0.97
3-year OS 3 1179 89 0 RE 1.06(0.62,1.81) 0.82
5-year OS 3 1179 94 0 RE 1.02(0.65,1.61) 0.94
p-mTOR Stomach 1-year OS 7 2269 0 0.75 FE 1.86(1.50,2.31) <0.001
3-year OS 7 2269 48 0.07 FE 1.71(1.52,1.93) <0.001
5-year OS 7 2269 70 0.003 RE 1.53(1.26,1.86) <0.001
  1. OS overall survival, RR risk ratio, CI confidence interval, FE fixed-effect model, RE random-effect model